CHC Healthcare Group Management
Management criteria checks 3/4
CHC Healthcare Group's CEO is Pei-Lin Lee, appointed in Jul 2018, has a tenure of 5.75 years. directly owns 6.34% of the company’s shares, worth NT$593.11M. The average tenure of the management team and the board of directors is 5.8 years and 9.8 years respectively.
Key information
Pei-Lin Lee
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.8yrs |
| CEO ownership | 6.3% |
| Management average tenure | 5.8yrs |
| Board average tenure | 9.8yrs |
Recent management updates
Recent updates
If You Had Bought CHC Healthcare Group's (TPE:4164) Shares Five Years Ago You Would Be Down 36%
Mar 08
CHC Healthcare Group's (TPE:4164) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 07
Should CHC Healthcare Group (TPE:4164) Be Part Of Your Dividend Portfolio?
Jan 21Is CHC Healthcare Group (TPE:4164) Likely To Turn Things Around?
Jan 06Is CHC Healthcare Group (TPE:4164) Using Too Much Debt?
Dec 22CHC Healthcare Group (TPE:4164) Share Prices Have Dropped 32% In The Last Five Years
Dec 07Are CHC Healthcare Group's (TPE:4164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Nov 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | NT$419m |
| Sep 30 2023 | n/a | n/a | NT$302m |
| Jun 30 2023 | n/a | n/a | NT$360m |
| Mar 31 2023 | n/a | n/a | NT$376m |
| Dec 31 2022 | n/a | n/a | NT$357m |
| Sep 30 2022 | n/a | n/a | NT$409m |
| Jun 30 2022 | n/a | n/a | NT$375m |
| Mar 31 2022 | n/a | n/a | NT$337m |
| Dec 31 2021 | NT$11m | NT$10m | NT$382m |
| Sep 30 2021 | n/a | n/a | NT$294m |
| Jun 30 2021 | n/a | n/a | NT$383m |
| Mar 31 2021 | n/a | n/a | NT$400m |
| Dec 31 2020 | NT$12m | NT$11m | NT$366m |
| Sep 30 2020 | n/a | n/a | NT$396m |
| Jun 30 2020 | n/a | n/a | NT$393m |
| Mar 31 2020 | n/a | n/a | NT$407m |
| Dec 31 2019 | NT$11m | NT$10m | NT$395m |
| Sep 30 2019 | n/a | n/a | NT$402m |
| Jun 30 2019 | n/a | n/a | NT$347m |
| Mar 31 2019 | n/a | n/a | NT$366m |
| Dec 31 2018 | NT$10m | NT$9m | NT$323m |
Compensation vs Market: Insufficient data to establish whether Pei-Lin's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Pei-Lin's compensation has been consistent with company performance over the past year.
CEO
Pei-Lin Lee
5.8yrs
Tenure
NT$11,059,000
Compensation
Mr. Pei-Lin Lee is Legal Director Representative of Huan Rui Medical Investment Holdings Co., Ltd. Mr. Lee has been Chairman of CHC Healthcare Group since November 25, 2012. Mr. Lee is General Manager of C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 5.8yrs | NT$11.06m | 6.34% NT$ 593.1m | |
| CFO, Corporate Governance Officer & Company Secretary | 5.1yrs | no data | 0.030% NT$ 2.8m | |
| Chief Executive Officer of Oncology Business Group | 9.9yrs | no data | 0.035% NT$ 3.3m |
5.8yrs
Average Tenure
Experienced Management: 4164's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.4yrs | NT$11.06m | 6.34% NT$ 593.1m | |
| Vice Chairman | 14.4yrs | NT$9.10m | 5.63% NT$ 526.5m | |
| Director | 9.8yrs | NT$848.00k | no data | |
| Independent Director | 9.8yrs | NT$956.00k | no data | |
| Director | 12.3yrs | NT$848.00k | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
9.8yrs
Average Tenure
Experienced Board: 4164's board of directors are considered experienced (9.8 years average tenure).